Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia
Mohana et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.10.031 (date from earlier preprint)
Mohana et al., Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi.., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.10.031 (date from earlier preprint)
Oct 2020   Source   PDF  
  All Studies   Meta
Safety study of 2,733 patients in Saudi Arabia showing HCQ in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and has minimal side effects. No ICU admission or deaths were reported.
Mohana et al., 17 Oct 2020, peer-reviewed, 15 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: International Journal of Infectious Diseases 102 (2021) 110–114 Contents lists available at ScienceDirect International Journal of Infectious Diseases journal homepage: Hydroxychloroquine safety outcome with an approved therapeutic protocol for COVID-19 outpatients in Saudi Arabia Abdulrhman Mohanaa,* , Tarek Sulaimanb , Nagla Mahmoudc , Mustafa Hassaneinc, Amel Alfaific , Eissa Alenazic , Nashwa Radwanc, Nasser AlKhalifahb , Ehab Elkadyc , Abdullah Almohaizeied, Fouad AboGazalahc , Khaled AlabdulKareemc , Fahad AlGhofailib , Hani Jokhdare , Fahad Alrabiahd a Saudi Centre for Disease Prevention and Control, 70 SCDC Building, Al Aarid, King Abdulaziz Rd, Riyadh 13354, Saudi Arabia King Fahad Medical City, 59046 Riyadh 11525, Saudi Arabia c Assisting Deputyship for Primary Health Care, Ministry of Health, 11176 Riyadh, Saudi Arabia d King Faisal Specialist Hospital and Research Centre, Zahrawi St, Al Maath, Al Maazer, Riyadh 12713, Saudi Arabia e Deputyship of Public Health, Ministry of Health, 11176 Riyadh, Saudi Arabia b A R T I C L E I N F O A B S T R A C T Article history: Received 20 August 2020 Received in revised form 7 October 2020 Accepted 10 October 2020 Background: Global health has been challenged by the COVID-19 pandemic since late 2019. Multiple approaches have been applied to relieve pressure on and support existing healthcare. The Saudi Arabian Ministry of Health (MOH) launched an initiative to support the national healthcare system. Since 5 June 2020, 238 outpatient fever clinics have been established nationwide. This study aimed to assess the safety outcome and reported adverse events from hydroxychloroquine use among suspected COVID-19 patients. Methods: The cross-sectional study included 2733 patients subjected to the MOH treatment protocol (hydroxychloroquine) and followed up for 3–7 days after initiation. Data were collected through an electronic link and cross-checked with the national database (Health Electronic Surveillance Network) and reports from the MOH Morbidity and Mortality Committee. Results: Two hundred and forty patients (8.8%) discontinued treatment because of side effects (4.1%) and non-clinical reasons (4.7%). Adverse effects were reported among 6.7% of all participants, including mainly cardiovascular symptoms (2.5%; 0.15% with corrected QT prolongation) and gastrointestinal symptoms (2.4%). No intensive care unit admission or death was reported among these patients. Conclusion: Our results show that hydroxychloroquine use for COVID-19 patients with mild to moderate symptoms in an outpatient setting with the recommended protocol and inclusion/exclusion criteria is safe, is highly tolerable and has minimal side effects. © 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( Keywords: Hydroxychloroquine COVID-19 Fever clinics Outpatient setting Safety outcome Infectious disease Background COVID-19 has rapidly emerged as a pandemic viral infection that has caused significant morbidity and death worldwide. Global * Corresponding author. E-mail addresses:, (A. Mohana), (T. Sulaiman), (N. Mahmoud), (M. Hassanein), (A. Alfaifi), (E. Alenazi),..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop